Bayer Trial Win Matters More than it Seems

Dow Jones10-30

1207 GMT - Bayer's win in a Missouri trial over the company's Roundup weedkiller is more meaningful than it might seem, given that it represents the first courtroom test of plaintiffs' alternative routes after a June ruling from the U.S. Supreme Court, analysts at Jefferies write in a note to clients. "While one verdict should not be over-extrapolated, we think it provides a positive first datapoint on plaintiffs' remaining litigation routes," the analysts say. The Supreme Court ruling pre-empted failure-to-warn claims, historically a key argument in Roundup litigation, they add. In the latest trial, the jury sided with Bayer's Monsanto on design defect, fraud and negligence claims and rejected them unanimously after a deliberation of just two hours, Jefferies says. Shares rise 3.6%.

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment